



Update on Formulary Access to VYNDAMAX and VYNDAQEL (tafamidis) for patients from Pfizer:

During the Medicare Open Enrollment period, some patients may have received letters stating that VYNDAMAX and/or VYNDAQEL may not be included on their health plan's formulary in 2025. We understand how this can raise concerns for patients. Keeping patients on therapy is of the utmost importance. We understand that some patients have questions, and we are committed to providing an appropriate level of support during this process.

Each year Medicare Part D plans review their prescription medicine formularies and make changes, which sometimes includes removing certain medicines. If you are reviewing your plan or selecting a new plan during the Medicare Open Enrollment period, it is possible that you may not see VYNDAMAX or VYNDAQEL included on the formulary. However, with many plans you may still be able to maintain and fill your current prescription for VYNDAMAX or VYNDAQEL even if it isn't listed.

If you don't see VYNDAMAX listed on your preferred Medicare Part D plan formulary, you can work with your healthcare team to request special permission, sometimes called a prior authorization or a formulary exception request. If you and your doctor think it's the right medicine for you, you can talk to them about it.

If you need additional assistance navigating this process, you can choose to get help from a Pfizer Patient Access Coordinator (PAC) for patients with a valid prescription. They can answer questions about insurance, getting the medicine, and associated costs. You can sign up for help at VyndamaxPAC.com. There are also some Medicare resources on the VYNDAMAX patient website (www.vyndamax.com/patient-resources).